Consun Pharmaceutical Group Limited (Consun Pharma) has filed its monthly return for the period ended 30 September 2026, detailing a modest contraction in share capital driven by market repurchases and a small inflow from option exercises.

Issued Capital • Authorised share capital remained unchanged at HKD 500.00 million, covering 5.00 billion ordinary shares with a par value of HKD 0.10 each. • Outstanding shares (excluding treasury stock) fell by 1.11 million to 837.94 million, a 0.13 % decline versus August. • Treasury shares increased by 1.26 million to 3.75 million, lifting total issued shares to 841.69 million. • The company confirmed public float compliance, maintaining at least 25 % of issued shares in public hands.

Share Option Activity • 143,683 options under the 2013 Share Option Scheme were exercised, generating HKD 0.53 million in proceeds at an average strike of HKD 3.71. • Post-exercise, 6.93 million options remain outstanding under the 2013 scheme. • The 2024 Share Option Scheme still carries capacity for up to 84.28 million shares, with no options granted or exercised to date.

Share Repurchases • Between 10 and 17 September, Consun Pharma executed five on-market buybacks totalling 1.26 million shares at an average price of HKD 13.11. • Aggregate cash outlay for the month’s repurchases is estimated at HKD 16.45 million, and all repurchased shares are held in treasury.

Capital Position Snapshot (30 Sep 2026) • Outstanding shares: 837.94 million • Treasury shares: 3.75 million • Total issued shares: 841.69 million

Compliance Statement The board confirmed that all share issuances and repurchases adhered to Hong Kong Listing Rules and relevant legal requirements, with all funds duly received.